Hepatocellular Carcinoma: A Guide to Screening and Diagnosis
|
|
|
- Berenice Ross
- 10 years ago
- Views:
Transcription
1 February 2012 Hepatocellular Carcinoma: A Guide to Screening and Diagnosis Reid Merryman, Harvard Medical School Year III
2 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 2
3 HCC: Epidemiology 20,000 new cases each year in the US 5 th most common cancer in men 7 th most common cancer in women Cirrhosis is present in 80-90% of patients diagnosed with HCC. Any condition leading to cirrhosis is considered an important risk factor HBV or HCV Alcoholic cirrhosis NAFLD NEJM. 2011;365:
4 HCC: A Global Disease - Burden of disease is greatest in developing countries, specifically those where HBV is endemic. El-Serag HB. NEJM. 2011;365: Worldwide, half a million cases of HCC are diagnosed each year. 4
5 HCC: Increasing Incidence in the US El-Serag HB. NEJM. 2011;365: The incidence of HCC in the United States has tripled in the last 30 years. 5
6 We have reviewed facts about risk factors and incidence of HCC. We will now discuss our index patient. 6
7 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment options Summary 7
8 Index Patient: Clinical Presentation I 56-year-old male with a history of alcohol-induced cirrhosis with multiple complications of ESLD Diuretic resistant ascites now improved status post TIPS placement (2007). Spontaneous bacterial peritonitis (SBP) now on Bactrim prophylaxis Hepatic encephalopathy (on lactulose and rifaximin). Grade II hemorrhoids Grade I varices 8
9 Index Patient: Clinical Presentation II Past medical history (continued) Non-insulin dependent Diabetes mellitus Hypothyroidism Anemia Ventral hernia repair He has ultrasound surveillance every three months to evaluate his TIPS shunt and to screen for HCC. Previous ultrasounds have shown no focal lesions and AFP has been within normal limits. 9
10 Before continuing with our index patient, we will pause to review indications for liver ultrasound screening and concerning findings on screening exams. 10
11 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment options Summary 11
12 HCC Surveillance We will discuss the following concepts. Who should be screened? What radiologic and non-radiologic studies should be used to screen? What results warrant additional testing? 12
13 HCC Surveillance: Screening population The American Association of Liver Diseases (AASLD) suggests screening in All patients with cirrhosis (annual incidence of HCC of 3-8%) Some patients with HBV (those whose annual incidence surpasses 0.2%) Asian men over 40 Asian women over 50 Africans and North African blacks Patients with a family history of HCC AASLD Practice Guideline, Management of Hepatocellular Carcinoma: An Update 13
14 HCC Surveillance: Evidence Zhang et al. J Cancer Res Clin Oncol. 2004;130: Evidence for screening is limited. One study randomized 18,816 people, aged years with HBV infection or chronic hepatitis in urban Shanghai to every 6 month screening with US and AFP or no screening. Demonstrated a 37% decrease in HCC-related mortality with screening over five years. 14
15 HCC Surveillance: Imaging Modality Ultrasound sensitivity varies widely depending on the study (55%-89%) but is equivalent to CT in most studies and is much more cost-effective. NEJM. 2011;365: Alimentary Pharmacology and Therapeutics. 2009;30:
16 Now that we know the evidence behind ultrasound surveillance, we will examine some examples of screening ultrasound. The images include examples of cirrhotic livers and various presentations of HCC. 16
17 Companion Patient 1: Cirrhotic liver on US Transverse US Findings: 1. Nodular liver surface 2. Ascites Irshad et al. Curr Probl Diagn Radiol. 2012;41:
18 Companion Patient 2: Nodular liver on US Transverse US Findings: 1. Extremely nodular liver with heterogeneous appearance. A nodular appearance decreases the sensitivity of ultrasound for identifying HCC. Irshad et al. Curr Probl Diagn Radiol. 2012;41:
19 Companion Patient 3: HCC Transverse US HCC can present with 1. single mass 2. multiple masses 3. diffuse disease Classically HCC lesions are hypoechoic. PACS BIDMC 19
20 Companion Patient 4: HCC Transverse US HCC can present with 1. single mass 2. multiple masses 3. diffuse disease Classically HCC lesions are hypoechoic. Irshad et al. Curr Probl Diagn Radiol. 2012;41:
21 Companion Patient 5: HCC Transverse US HCC can present with 1. single mass 2. multiple masses 3. diffuse disease Classically HCC lesions are hypoechoic. Irshad et al. Curr Probl Diagn Radiol. 2012;41:
22 Companion Patient 6: HCC Transverse US However HCC can present with varying echogenicity. Findings: Two hyperechoic liver masses that were found to be HCC Irshad et al. Curr Probl Diagn Radiol. 2012;41:
23 We have seen multiple classic examples of HCC on ultrasounds. We will now examine our patient s screening ultrasound exam. 23
24 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 24
25 Index Patient: Isoechoic lesion on US Transverse US Findings 1. Diffusely heterogenous echotexture. 2. Isoechoic lesion with hypoechoic rim. PACS BIDMC 25
26 Index Patient: Focal Lesion Transverse and Saggital US Findings: Isoechoic lesion with hypoechoic rim. PACS BIDMC 26
27 Index Patient: Lesion Dimensions Transverse and Saggital US Findings: Isoechoic lesion with hypoechoic rim measuring 1.2 x2.3 x1.2 cm. PACS BIDMC 27
28 Index Patient: Review of Findings Coarsened and nodular liver A suspicious mass in the right lobe of the liver (segment IVa) measuring 1.2 x 2.3 x 1.2 cm The mass is isoechoic with a hypoechoic rim. 28
29 Before discussing a differential diagnosis for our index patient s liver findings, we will briefly review segmental liver anatomy. 29
30 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment options Summary 30
31 Liver Anatomy: Segment IVa Our patient s lesion was visualized in Section IVa. Medscape. Ultrasoundpaedia: A portal to the world of ultrasound. 31
32 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 32
33 DDx: Focal Liver Lesion Benign liver masses 1. Cysts 2. Hemangioma 3. Focal nodular hyperplasia 4. Hepatic adenoma 5. Biliary cystadenoma 6. Abscess 7. Hematoma 8. Regenerating nodules 9. Confluent hepatic fibrosis Malignant liver masses 1. HCC 2. Metastases 3. Intrahepatic Cholangiocarcinoma 4. Lymphoma 5. Stromal tumors 33
34 DDx: Focal Liver Lesion -Patient has a cirrhotic liver Benign liver masses 1. Cysts 2. Hemangioma 3. Focal nodular hyperplasia 4. Hepatic adenoma 5. Biliary cystadenoma 6. Abscess 7. Hematoma 8. Regenerating nodules * 9. Confluent hepatic fibrosis * Malignant liver masses 1. HCC * 2. Metastases 3. Intrahepatic Cholangiocarcinoma 4. Lymphoma 5. Stromal tumors 34
35 DDx: Focal Liver Lesion -Patient has a cirrhotic liver -Isoechoic mass with hypoechoic rim Benign liver masses 1. Cysts 2. Hemangioma 3. Focal nodular hyperplasia * 4. Hepatic adenoma * 5. Biliary cystadenoma 6. Abscess 7. Hematoma 8. Regenerating nodules * 9. Confluent hepatic fibrosis * Malignant liver masses 1. HCC ** 2. Metastases 3. Intrahepatic Cholangiocarcinoma 4. Lymphoma 5. Stromal tumors 35
36 We have prioritized our differential diagnosis for our index patient s liver lesion based on his history and ultrasound findings. We will now discuss an evidence-based work-up. 36
37 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 37
38 Diagnostic Imaging: ACR Guidelines American College of Radiology Appropriateness Criteria 2010 MR has greater sensitivity than CT for detecting HCC especially in cirrhotic livers and is recommended for diagnostic imaging. 38
39 Diagnostic Imaging: Liver Protocol Liver imaging for both MRI and CT uses a liver protocol which includes a non-contrast study followed by 3 phase contrast-enhanced liver imaging: - Arterial phase - Venous phase - Delayed phase Radiology. 2008;247:
40 Diagnostic Imaging: Characteristic Findings for HCC on MRI There are several findings that suggest that a liver lesion is HCC on MRI including: - The lesion is hypointense on T1 - The lesion is hyperintense on T2 - The lesion shows enhancement on arterial phase with iso- or hypointensity on venous and delayed phases ( washout ) *Arterial phase enhancement with delayed phase washout is the most specific finding and is part of the radiologic diagnostic criteria for HCC. Radiology. 2008;247:
41 Diagnostic Imaging: Explanation for Arterial enhancement Liver tissue typically receives most of its blood supply from the portal system with a smaller portion from the hepatic artery. In HCC, neoangiogenesis alters that basic relationship. There is a diminution of portal tracts and virtually all of the blood supply is via the hepatic artery. This specific findings allows for distinction from regenerating or dysplastic nodules which can otherwise closely mimic HCC on imaging. Radiology. 2008;247:
42 We have discussed characteristic imaging findings for HCC. Now let s look at some companion patients with HCC on MRI and CT. 42
43 Companion Patient 7: HCC on MRI Axial T1 arterial phase Axial T1 venous phase Finding: Two liver lesions with arterial enhancement with venous and delayed phase washout. Axial T1 delayed phase Radiology. 2008;247:
44 Companion Patient 3: HCC on MRI Axial T1 pre-contrast Axial T1 arterial phase PACS BIDMC Axial T1 venous phase Axial T1 delayed phase 44
45 Companion Patient 3: HCC on MRI Finding: A 3.0 cm liver lesion near the falciform ligament is iso-intense on pre-contrast T1 imaging and shows arterial enhancement with venous and delayed phase washout on contrast imaging 45
46 Companion Patient 3: HCC on CT Axial CT arterial phase Axial CT delayed phase PACS BIDMC Findings: CT shows same classic findings as MR: arterial enhancement with delayed phase washout. 46
47 We have learned classic examples of HCC on T1 multiphase MRI and on multiphase CT. Now let s examine our index patient s MRI exam. 47
48 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 48
49 Index Patient: HCC on MRI Axial T1 arterial phase Axial T1 venous phase PACS BIDMC Axial T1 delay 1 phase Axial T1 delay 2 phase 49
50 Index Patient: MRI Findings Findings: - Nodular cirrhotic liver cm lesion in segment IVa. - The lesion isointense in T1 and T2 (not shown) but shows arterial enhancement and washout pattern in venous and delayed phases (with significant motion artifact) 50
51 Index Patient: Diagnosis of HCC Our index patient has 1. A lesion greater than 2cm AND 2. Arterial enhancement with venous and delayed phase washout. Based on these findings, a diagnosis of HCC can be made. What are our patient s treatment options? 51
52 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 52
53 Treatment: Surgical resection Depends on the number, size, and location, as well as the patient's functional status. 1. Surgical resection A. favor for lesions which are in a good location and for suitable surgical candidates. B. Can be curative but leaves the patient with a susceptible liver. 2. Liver transplant 3. Minimally invasive/local-regional treatment NEJM. 2011;365:
54 Treatment: Transplant Depends on the number, size, and location, as well as the patient's functional status. 1. Surgical resection 2. Liver transplant A. Equivalent or better outcomes than surgical resection B. Patient must meet Milan criteria - one lesion smaller than 5cm. - up to 3 lesions smaller than 3 cm. - no extrahepatic manifestations - no vascular invasion 3. Minimally invasive local-regional treatment NEJM. 2011;365:
55 Treatment: Local Therapy Depends on the number, size, and location, as well as the patient's functional status. 1. Surgical resection 2. Liver transplant 3. Minimally invasive local-regional treatment - 1. Useful in certain patient populations (ie poor performance status, expected to receive a transplant in the future) 2. Short-term outcomes are excellent, but long-term outcomes are inferior to above treatments. 3. Methods include: - Transarterial chemoembolization [TACE] - Percutaneous ethanol infusion (PEI) - Radiofrequency ablation (RFA) - Cryotherapy NEJM. 2011;365:
56 Index Patient: Radiofrequency Ablation -Our patient was not a good surgical candidate and opted to undergo radiofrequency ablation. -Under ultrasound guidance, a 20-cm long RF electrode was advanced to the site of the lesion and two 12 minute 1200 mamp ablations were performed. Axial non-contrast CT Axial non-contrast CT PACS BIDMC 56
57 Index Patient: Post-RFA Post-RFA Findings: -Ablation zone measuring 25 x 41 mm surrounded by reactive hyperemia. Axial non-contrast CT PACS BIDMC 57
58 Index Patient: Follow-up - One month later the patient had ultrasound and CT which showed no new concerning lesions. - He is scheduled for additional ultrasound and CT in three months and is currently clinically stable. 58
59 Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation Surveillance for HCC Index patient: screening ultrasound Anatomy review Index patient: Differential Diagnosis Diagnostic imaging for HCC Index patient: Diagnostic imaging Treatment and Outcome Summary 59
60 Summary - Hepatocellular carcinoma is a common cancer associated with cirrhosis and viral hepatitis. Its incidence is increasing. - Surveillance ultrasound every 3-6 months is recommended for all patients with cirrhosis and many patients with HBV. - Concerning lesions on screening ultrasound should be followed up with MRI which has higher sensitivity for assessing lesions than CT particularly in cirrhotic livers. -Arterial enhancement with venous and delayed phase washout is highly specific for HCC. - There are numerous treatment options for HCC which are selected based on the number, size, and location of lesions, as well as the patient's functional status 60
61 Student Name, year Acknowledgements Dr. Michael Acord Dr. Wei Dr. Gillian Lieberman 61
62 Student Name, year References El-Serag HB. Current concepts: Hepatocellular carcinoma. NEJM. 2011;365: Irshad A, Munazza A, and Ackerman SJ. Current role of ultrasound in chronic liver disease: surveillance, diagnosis, and management of hepatic neoplasms. Curr Probl Diagn Radiol. 2012;41: Willatt, JM, Hussain HK, Adusumilli A, et al. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247: Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early stage hepatocellular carcinoma in patients with cirrhosis. Alimentary Pharmacology and Therapeutics. 2009;30:37-47 AASLD Practice Guideline, Management of Hepatocellular Carcinoma: An Update. Bruix, J, Sherman, M. Guidelines/HCCUpdate2010.pdf Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130: Von Herbay A, Frieling T, Niederau C, et al. Solitary hepatic lesions with a hypoechoic rim: value of color Doppler sonography. AJR. 1997;169: Libbrecht L, Bielen D, Verslype C. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 2002;8:749. Liver lesion initial characterization. American College of Radiology ACR Appropriateness Criteria Medscape. (Accessed 2/20/2012) Ultrasoundpaedia: A portal to the world of ultrasound. (Accessed 2/20/2012) 62
Surveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL HEPATOCELLULAR CARCINOMA GI Site Group Hepatocellular Carcinoma Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION. Francis Yao, M.D.
UCSF TRANSPLANT CONFERENCE - 9/28/2012 HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation
Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
Benign Liver Tumors. Cameron Schlegel PGY-1 3/6/2013
Benign Liver Tumors Cameron Schlegel PGY-1 3/6/2013 Outline Benign Liver Tumors are, in general. Asymptomatic Diagnosed: imaging Treatment: Do no harm Unless Malignant potential Causing symptoms Differential
LIVER CANCER AND TUMOURS
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
Hepatocellular Carcinoma: What the hepatologist wants to know
Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations. Chapter. Grade. CQ No. 1 Interferon Therapy
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations Chapter Chapter 1 Prevention Sectio n CQ No. 1 Interferon Therapy Clinical Question 1 Does interferon
CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA
CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA WHAT IS CANCER OF THE LIVER? Hepatocellular carcinoma is the most common form and it comes from the main type of liver cell, the hepatocyte. About 3 out 4
Hepatocellular Carcinoma Management Guidelines
Hepatocellular Carcinoma Management Guidelines By Ashraf Omar M.D, Prof. of Hepatology & Tropical Medicine Cairo University Staging Strategy and Treatment for Patients With HCC HCC PST 0, Child-Pugh A
LIVER TUMORS PROFF. S.FLORET
LIVER TUMORS PROFF. S.FLORET NEOPLASM OF LIVER PRIMARY 1)BENIGN 2)MALIGNANT METASTATIC/SECONDARY LIVER Primary Liver Cancer the Second Killer among tumors high morbidity and mortality(20.40/100,000) etiology
Hepatocellular Carcinoma Treatment Decision Tree
Treatment Decision Tree Derek DuBay, MD Assistant Professor of Surgery Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery 1 UAB Liver Tumor Clinic Referrals: 205 996 5970 (phone) 205
NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
THE SECOND VERSION of Evidence-based Clinical
bs_bs_banner doi: 10.1111/hepr.12464 Special Report Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) Norihiro
UK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults
UK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults SD Ryder DM FRCP Consultant Hepatologist Queens Medical Centre Nottingham University Hospitals NHS Trust Wolfson Digestive
Contrast-Enhanced Ultrasound (CEUS)
Contrast-Enhanced Ultrasound (CEUS) Odd Helge Gilja, MD, PhD Professor Department of Medicine Haukeland University Hospital Bergen, Norway The Micro-Bubble Contrast Agents - World View IEEE Transactions
Optimal imaging surveillance schedules after liver directed therapy for hepatocellular carcinoma
Optimal imaging surveillance schedules after liver directed therapy for hepatocellular carcinoma F. Edward Boas, MD, PhD; Bao Do, MD; John D. Louie, MD; Nishita Kothary, MD; Gloria L. Hwang, MD; William
ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions
PRACTICE GUIDELINES nature publishing group 1 ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions Jorge A. Marrero, MD1, Jo s e ph A h n, M D, FAC G 2 and K. Rajender Reddy, MD,
Hepatitis C Infections in Oregon September 2014
Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with
Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.
Review Med Ultrason 2014, Vol. 16, no. 2, 139-144 DOI: 10.11152/mu.2013.2066.162.md1is2 Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Mirela Dănilă,
Geir Folvik, MD Division of Gastroenterology Department of Medicine, Haukeland University Hospital Bergen, Norway 30.11.2015
Benign liver diseases Geir Folvik, MD Division of Gastroenterology Department of Medicine, Haukeland University Hospital Bergen, Norway 30.11.2015 1 Agenda Benign focal liver lesions Fatty liver disease
Hepatocellular Carcinoma and Y-90 Radioembolization
Hepatocellular Carcinoma and Y-90 Radioembolization Radhika S. Kumar, MD Faculty Advisors: Ravi Shridhar, MD PhD, Michael Montejo, MD, Bela Kis, MD and Ghassan El- Haddad, MD H.L. Moffitt Cancer Center
DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Measure #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
New Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma. Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma
New Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma Riccardo Lencioni Author s Affiliation: Division of Diagnostic
Evaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
MRI of Benign Liver Lesions and Metastatic Disease Characterization with. Gadoxetate Disodium
MRI of Benign Liver Lesions and Metastatic Disease Characterization with Gadoxetate Disodium Rocky C. Saenz, D.O. Department of Diagnostic Radiology, Botsford Hospital, Farmington Hills, MI Introduction
SBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs.
Uitgangsvraag 6: Wat is de plaats van stereotactische radiotherapiebehandeling (SBRT) bij HCC patiënten? Primaire studies I Study ID II Method III Patient characteristics IV Intervention(s) V Results primary
Hepatocellular Carcinoma (HCC)
Abhishek Vadalia Introduction Chemoembolization is being used with increasing frequency in the treatment of solid hepatic tumors such as Hepatocellular Carinoma (HCC) & rare Cholangiocellular Carcinoma
Breast Ultrasound: Benign vs. Malignant Lesions
October 25-November 19, 2004 Breast Ultrasound: Benign vs. Malignant Lesions Jill Steinkeler,, Tufts University School of Medicine IV Breast Anatomy Case Presentation-Patient 1 62 year old woman with a
Treatment of Hepatic Neoplasm
I. Policy University Health Alliance (UHA) will reimburse for treatment of hepatic neoplasm outside of systemic chemotherapy alone when determined to be medically necessary and within the medical criteria
Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe
2235-1795/15/0042-0085$39.50/0 85 Editorial Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe Prof. M. Kudo Editor Liver Cancer Introduction Hepatocellular
What is liver cancer?
Liver Cancer What is liver cancer? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines LIVER CANCER: A GUIDE FOR PATIENTS
190.25 - Alpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
To Whipple or Not to Whipple, that is the Question: Evaluating the Resectability of Pancreatic Adenocarcinoma
August 2009 To Whipple or Not to Whipple, that is the Question: Evaluating the Resectability of Pancreatic Adenocarcinoma Christina Ramirez, Harvard Medical School Year III Gillian Lieberman, MD Agenda
COMPLICATIONS OF CIRRHOSIS COMPLICATIONS OF CIRRHOSIS OBSERVATIONS OF AN AGING HEPATOLOGIST. Philip C. Delich, M.D.
1 COMPLICATIONS OF CIRRHOSIS OBSERVATIONS OF AN AGING HEPATOLOGIST COMPLICATIONS OF CIRRHOSIS Philip C. Delich, M.D. Faculty Disclosure Dr. Delich has indicated that he does not have any relevant financial
Liver Diseases. An Essential Guide for Nurses and Health Care Professionals
Brochure More information from http://www.researchandmarkets.com/reports/1047385/ Liver Diseases. An Essential Guide for Nurses and Health Care Professionals Description: Liver disease is a rapidly growing
Characterization of small renal lesions: Problem solving with MRI Gary Israel, MD
Characterization of small renal lesions: Problem solving with MRI Gary Israel, MD With the widespread use of cross-sectional imaging, many renal masses are incidentally found. These need to be accurately
A PATIENT S GUIDE TO ABLATION THERAPY
A PATIENT S GUIDE TO ABLATION THERAPY THE DIVISION OF VASCULAR/INTERVENTIONAL RADIOLOGY THE ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL Treatment options for patients with cancer continue to expand, providing
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 6
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 6 Contents 6. Hepatocellular carcinoma 64 6.1. Introduction: 65 6.2.
MANAGEMENT OF LIVER CIRRHOSIS
MANAGEMENT OF LIVER CIRRHOSIS Information Leaflet Your Health. Our Priority. Page 2 of 6 What is cirrhosis? Cirrhosis is a result of long-term, continuous damage to the liver and may be due to many different
Kidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
Management of Spontaneous Rupture of Liver Tumours
Complications in Hepatobiliary Surgery Dig Surg 2002;19:109 113 P. Marini a V. Vilgrain b J. Belghiti a Departments of a Hepatopancreatobiliary Surgery and b Radiology, Beaujon Hospital, Assistance Publique,
BERGEN COMMUNITY COLLEGE DIAGNOSTIC MEDICAL SONOGRAPHY PROGRAM Division of Health Professions DMS 213 SYLLABUS
BERGEN COMMUNITY COLLEGE DIAGNOSTIC MEDICAL SONOGRAPHY PROGRAM Division of Health Professions DMS 213 SYLLABUS Course Title: DMS 213 - Abdominal Sonography 2 2 lec. 3 lab. 3 credits (5 hours) Required
Treatment Advances for Liver Cancer
Treatment Advances for Liver Cancer Guest Expert: Wasif, MD Associate Professor of Medical Oncology Mario Strazzabosco, MD Professor of Internal Medicine, Digestive Diseases www.wnpr.org www.yalecancercenter.org
Portal Vein Thrombosis. Sophia A. Virani, HMS III Gillian Lieberman, MD Beth Israel Deaconess Medical Center Department of Radiology March 2009
Portal Vein Thrombosis Sophia A. Virani, HMS III Gillian Lieberman, MD Beth Israel Deaconess Medical Center Department of Radiology March 2009 Agenda Introduce index patient Discuss portal vein thrombosis
ABR Certifying Exams In Diagnostic Radiology. Early Results Future Considerations
ABR Certifying Exams In Diagnostic Radiology Early Results Future Considerations 1 Exam Goals: Core Overarching goal: to protect the public by determining that individual candidates have attained competence
June 11, 2015 Tim Halterman
June 11, 2015 Tim Halterman Defini&on Histologic change + loss of liver function Derives from Greek word kirrhos meaning yellow, tawny First named by Rene Laennec in 1819 Laennec s cirrhosis=alcoholic
Spleen. Anatomy. (Effective February 2007) (1%-5%) Normal. Related Anatomy Anterior to spleen. Medial border. Posteriorly
Spleen (Effective February 2007) (1%-5%) Anatomy Normal Intraperitoneal, except hilum Left hypochondrium Left hemidiaphragm superior generally considered to be ovoid, with a convex superior and a concave
Leading the Way to Treat Liver Cancer
Leading the Way to Treat Liver Cancer Guest Expert: Sukru, MD Professor of Transplant Surgery Mario Strazzabosco, MD Professor of Internal Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale
Recanalized Umbilical Vein in the Presence of Cirrhosis-Induced Portal Hypertension
Recanalized Umbilical Vein in the Presence of Cirrhosis-Induced Portal Hypertension Audrey Galey RDMS, RVT, Mary Grace Renfro RDSM, RVT, Lindsey Simon, RVT March 22, 2013 2 Abstract A recanalized umbilical
Moving Beyond RECIST
Moving Beyond RECIST Ihab R. Kamel, M.D., Ph.D. [email protected] Associate Professor Clinical Director, MRI Department of Radiology The Johns Hopkins University School of Medicine Outline Standard measures
Hepatocellular carcinoma: Algorithms of diagnosis and options of therapy
Hepatocellular carcinoma: Algorithms of diagnosis and options of therapy Alejandro Forner BCLC Group. Liver Unit. Hospital Clinic. University of Barcelona Pathogenesis and Clinical Practice in Gastroenterology
The State of the Liver in the Adult Patient after Fontan Palliation
The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital
Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
POSTMENOPAUSAL ASSESS AND WHAT TO DO
POSTMENOPAUSAL OVARIAN CYSTS:HOW TO ASSESS AND WHAT TO DO Steven R. Goldstein, MD Professor of Obstetrics and Gynecology Director of Gynecologic Ultrasound Co-Director, Bone Densitometry New York University
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
Hepatocellular Carcinoma (Liver Cancer):
Hepatocellular Carcinoma (Liver Cancer): Introduction Headed by Dr. Ahmet Gurakar, our team of full-time faculty members specializing in liver cancer includes: Ahmet Gurakar, M.D. James P. Hamilton, M.D.
Cirrhosis and HCC. Dr.Abonyi Margit PhD SE 1st.Medical Clinic
Cirrhosis and HCC Dr.Abonyi Margit PhD SE 1st.Medical Clinic 2011 1 Cirrhosis 6.000-8.000 deaths in Hungary A 4. cause of death in Hungary Kb. 1.000.000 suffering of chronic hepatic problem M:F 2:1 5-20
Seeing the Unseen New Techniques in Vascular Imaging
M edical R eview Seeing the Unseen New Techniques in Vascular Imaging Superb Micro-Vascular Imaging M edical R eview Seeing the Unseen New Techniques in Vascular Imaging Superb Micro-Vascular Imaging Dr.
Hepatocellular carcinoma: ESMO ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 23 (Supplement 7): vii41 vii48, 2012 doi:10.1093/annonc/mds225 Hepatocellular carcinoma: ESMO ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up C. Verslype 1,2,
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); [email protected] Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
Sovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
UCLA Asian Liver Program
CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,
Indications in Hepatology and Liver Diseases
exclusively working in Health Care sananet GmbH Tilo Stolzke Breite Str. 6-8 23562 Lübeck Germany Telefon : +49 451 400 8301 Telefax : +49 451 400 8302 E-Mail : [email protected] Internet : www.sananet.com
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
AASLD PRACTICE GUIDELINE. Management of Hepatocellular Carcinoma: An Update. Surveillance and Diagnosis. Staging and Treatment of HCC
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update Jordi Bruix, 1 and Morris Sherman 2 Since the publication of the American Association for the Study of Liver Diseases (AASLD)
New IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
Diagnosis, staging and treatment of hepatocellular carcinoma
Brazilian Hepatocellular Journal carcinoma of Medical and Biological Research (2004) 37: 1689-1705 ISSN 0100-879X Review 1689 Diagnosis, staging and treatment of hepatocellular carcinoma A.V.C. França
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,
Lenox Hill Hospital Department of Surgery General Surgery Goals and Objectives
Lenox Hill Hospital Department of Surgery General Surgery Goals and Objectives Medical Knowledge and Patient Care: Residents must demonstrate knowledge and application of the pathophysiology and epidemiology
Case Report. Central Neurocytoma. Fotis Souslian, MD; Dino Terzic, MD; Ramachandra Tummala, MD. Department of Neurosurgery, University of Minnesota
1 Case Report Central Neurocytoma Fotis, MD; Dino Terzic, MD; Ramachandra Tummala, MD Department of Neurosurgery, University of Minnesota Case This is a previously healthy 20 year old female, with 3 months
Pancreatic Cancer. The Killer that must be discovered early. Dr Alfred Kow Wei Chieh
Pancreatic Cancer The Killer that must be discovered early 27 th June 2015 Dr Alfred Kow Wei Chieh Consultant Department of Surgery Division of HPB Surgery & Liver Transplantation & Assistant Dean (Education)
Hepatocellular carcinoma: A comprehensive review
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4254/wjh.v7.i26.2648 World J Hepatol 2015 November 18; 7(26): 2648-2663 ISSN 1948-5182 (online)
PROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
Hepatocellular Carcinoma
Hepatocellular Carcinoma GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Walter Kocha, MD, FRCPC (Medical Oncologist) Approval Date: October 2006 This guideline is a statement of
Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care
Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:
Approach to Lower Extremity Osteomyelitis. A radiologic tour of a patient encounter
Approach to Lower Extremity Osteomyelitis A radiologic tour of a patient encounter David Guo,, HMS III Gillian Lieberman, MD BIDMC, October 2009 Our learning goals Review lower extremity anatomy Discuss
Cirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
Focal Treatment of Liver Metastasis. Bjørn Skjoldbye The Gastro Unit Herlev Hospital
Focal Treatment of Liver Metastasis Bjørn Skjoldbye The Gastro Unit Herlev Hospital The Classic approach: Liver metastasis CRC Resectable? Operable? Chemotherapy Surgery Potential cureable disease Liver
Frozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
EASL EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
Clinical Practice Guidelines EASL EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver, European Organisation for Research and Treatment
